Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,168 shares of the biopharmaceutical company's stock after purchasing an additional 649 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Regeneron Pharmaceuticals were worth $24,220,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Marietta Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares in the last quarter. GAMMA Investing LLC boosted its stake in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after purchasing an additional 955 shares in the last quarter. KBC Group NV boosted its stake in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after purchasing an additional 12,793 shares in the last quarter. Finally, Lmcg Investments LLC boosted its stake in Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock worth $9,184,000 after purchasing an additional 10,110 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Stock Down 1.5%

Regeneron Pharmaceuticals stock traded down $8.68 during mid-day trading on Friday, hitting $589.48. The company had a trading volume of 1,438,624 shares, compared to its average volume of 1,111,801. The stock has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 1.97 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $549.27 and a 200 day moving average of $592.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $11.56 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.